Moderate to Severe Psoriasis Clinical Trial
Multicentre, open label, phase III study. Subjects with moderate to severe psoriasis were given efalizumab subcutaneously once per week for the 12-week treatment period. Assessments involved physical examination, disease activity assessments, clinical laboratory tests (haematology, blood chemistry and standard urinalysis), evaluation of the Psoriasis Area and Severity Index (PASI), the Physician's Global Assessment (PGA), the Patient's Global Psoriasis Assessment (PGPA), the SF-36 Health Survey and psoriatic body surface area (BSA). The 12-week treatment period was followed by a 12-week follow-up (FU) period, during which other antipsoriatic medications were allowed. The same assessments were also performed in the 12-week FU period.
n/a
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00678470 -
Open Label Study of Alefacept Injections to Patients With Moderate to Severe Psoriasis
|
N/A | |
| Terminated |
NCT01156532 -
Clinical Effectiveness and Impact on Health-related Quality of Life in Peruvian Patients With Psoriasis After 16 Weeks of Adalimumab Therapy
|
N/A | |
| Completed |
NCT00256139 -
CLEAR Study: Clinical Experience Acquired With Raptiva Study
|
Phase 3 | |
| Completed |
NCT00936065 -
Study Evaluating the Efficacy and Safety of Etanercept and Acitretin in Korean Patient With Moderate to Severe Psoriasis
|
Phase 4 | |
| Completed |
NCT05344248 -
Safety, Tolerance, Efficacy and Pharmacokinetics of JS005 Multiple Dosing
|
Phase 1/Phase 2 | |
| Completed |
NCT03051217 -
A Study to Test the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic Psoriasis
|
Phase 2/Phase 3 |